Table 3 Proteasome inhibitor related cardiac adverse events
From: Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
Cardiac adverse event, n | Bortezomib (n = 44) | Carfilzomib (n = 52) | Total (n = 96) |
|---|---|---|---|
Any typea | 7 | 14 | 21 |
Heart failure | 6 | 7 | 13 |
Grade 3 or 4 | 3 | 4 | 7 |
Systemic hypertension | 1 | 3 | 4 |
Grade 3 or 4 | 1 | 3 | 4 |
Thromboembolism | 1 | 2 | 3 |
Grade 3 or 4 | 0 | 0 | 0 |
Acute coronary syndrome | 1 | 1 | 2 |
Grade 3 or 4 | 1 | 0 | 1 |
Atrial fibrillation/flutter | 0 | 2 | 2 |
Grade 3 or 4 | 0 | 1 | 1 |
Pulmonary hypertension | 0 | 1 | 1 |
Grade 3 or 4 | 0 | 1 | 1 |
Orthostatic hypotension | 0 | 0 | 0 |
Sudden cardiac death | 0 | 0 | 0 |